Abstract
The metabolic fate of the tyrosine hydroxylase inhibitor, α-methyl-para-tyrosine (α-MPT), was studied after oral administration of single and multiple doses to patients with pheochromocytoma and essential hypertension. No major urinary excretion product was found other than the drug itself, which accounted for 44-88% of the fate of single or repeated oral doses. Though less than 1% of the administered drug could be recovered in the urine as catechol metabolites, it was possible to identify α-methyldopa, α-methyldopamine, and α-methylnorepinephrine and to quantify the excretion of the first two of these compounds. This minor route of metabolism required revision of methodology (presented herein) for measuring urinary catecholamines during α-MPT treatment since these compounds produce spurious fluorescence in routine methods of assay for catecholamines. The catechol metabolites probably are not present in sufficient amounts to contribute to the biochemical effects of the drug. Determination of plasma concentrations of α-MPT during maintenance therapy and considerations of the kinetics of enzyme inhibition enabled a calculation to be made of the degree of inhibition of catecholamine synthesis to be expected in the patient. This was calculated to be about 75% for the highest doses employed and is similar in magnitude to experimentally determined values.
Full text
PDF
Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Engelman K., Horwitz D., Jéquier E., Sjoerdsma A. Biochemical and pharmacologic effects of alpha-methyltyrosine in man. J Clin Invest. 1968 Mar;47(3):577–594. doi: 10.1172/JCI105754. [DOI] [PMC free article] [PubMed] [Google Scholar]
- FLODING I., VON EULER U. S. Diagnosis of pheochromocytoma by fluorimetric estimation of adrenaline and noradrenaline in urine. Scand J Clin Lab Invest. 1956;8(4):288–295. doi: 10.3109/00365515609049286. [DOI] [PubMed] [Google Scholar]
- ROBERTS M. A note on the use of cellulose phosphate cation-exchange paper for the separation of catecholamines, and some other biogenic amines. J Pharm Pharmacol. 1962 Nov;14:746–749. doi: 10.1111/j.2042-7158.1962.tb11170.x. [DOI] [PubMed] [Google Scholar]
- SJOERDSMA A., VENDSALU A., ENGELMAN K. STUDIES ON THE METABOLISM AND MECHANISM OF ACTION OF METHYLDOPA. Circulation. 1963 Oct;28:492–502. doi: 10.1161/01.cir.28.4.492. [DOI] [PubMed] [Google Scholar]
- SPECTOR S., SJOERDSMA A., UDENFRIEND S. BLOCKADE OF ENDOGENOUS NOREPINEPHRINE SYNTHESIS BY ALPHA-METHYL-TYROSINE, AN INHIBITOR OF TYROSINE HYDROXYLASE. J Pharmacol Exp Ther. 1965 Jan;147:86–95. [PubMed] [Google Scholar]
- Sjoerdsma A., Engelman K., Spector S., Udenfriend S. Inhibition of catecholamine synthesis in man with alpha-methyl-tyrosine, an inhibitor of tyrosine hydroxylase. Lancet. 1965 Nov 27;2(7422):1092–1094. doi: 10.1016/s0140-6736(65)90062-0. [DOI] [PubMed] [Google Scholar]
- Stone C. A., Porter C. C. Methyldopa and adrenergic nerve function. Pharmacol Rev. 1966 Mar;18(1):569–575. [PubMed] [Google Scholar]
- Udenfriend S., Zaltzman-Nirenberg P., Gordon R., Spector S. Evaluation of the biochemical effects produced in vivo by inhibitors of the three enzymes involved in norepinephrine biosynthesis. Mol Pharmacol. 1966 Mar;2(2):95–105. [PubMed] [Google Scholar]
- Udenfriend S., Zaltzman-Nirenberg P., Nagatsu T. Inhibitors of purified beef adrenal tyrosine hydroxylase. Biochem Pharmacol. 1965 May;14(5):837–845. doi: 10.1016/0006-2952(65)90103-6. [DOI] [PubMed] [Google Scholar]
- WAALKES T. P., UDENFRIEND S. A fluorometric method for the estimation of tyrosine in plasma and tissues. J Lab Clin Med. 1957 Nov;50(5):733–736. [PubMed] [Google Scholar]